Hospital San Pedro De Alcantara

At Hospital San Pedro De Alcantara in Caceres, much of the clinical research focuses on hematologic malignancies and related blood disorders. Studies are aimed at improving treatment effectiveness, testing new combinations, and finding better options for people with difficult-to-treat disease.

• Acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia
• Multiple myeloma and plasma cell disorders
• Lymphomas such as diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia

The site’s work in hematology is especially active in evaluating new therapies for relapsed or high-risk disease, with the goal of improving response rates and long-term outcomes.

Another major research area at this Spanish hospital is oncology, particularly breast cancer and other solid tumors. These trials are designed to refine treatment choices, support earlier intervention, and help match therapy to tumor biology.

• HER2-positive, HR-positive, and HER2-negative breast cancer
• Triple-negative breast cancer and advanced metastatic breast cancer
• Melanoma, ovarian cancer, pancreatic cancer, and lung cancer

Research here often evaluates new targeted and immune-based approaches, as well as strategies to improve outcomes after surgery or in advanced disease.

Clinical trials also cover genitourinary cancers, with a strong focus on bladder cancer, prostate cancer, and kidney cancer. The purpose is to improve disease control, reduce recurrence, and broaden treatment options for patients with localized or advanced disease.

• Muscle-invasive and non-muscle invasive bladder cancer
• Metastatic prostate cancer
• Renal cell carcinoma and recurrence prevention after surgery

These studies reflect a growing interest in both immunotherapy and perioperative treatment approaches to improve outcomes in urologic cancers.

The site’s portfolio includes research in immune system diseases and rare inflammatory conditions, alongside selected non-malignant blood disorders. These trials aim to better control inflammation, prevent disease flares, and compare newer therapies with established care.

• Paroxysmal nocturnal hemoglobinuria and immune thrombocytopenia
• Myelofibrosis and neutropenia linked to intensive cancer treatment
• Autoinflammatory diseases and other rare immune-mediated disorders

Work in this area combines diagnostic and therapeutic research to support more precise and better-tolerated care.

Beyond cancer and hematology, Hospital San Pedro De Alcantara participates in trials across cardiovascular disease, respiratory disease, and selected neurologic conditions. These studies focus on improving prevention, symptom control, and long-term disease management.

• Acute coronary syndromes, atherosclerotic cardiovascular disease, and aortic valve stenosis
• Chronic obstructive pulmonary disease and asthma
• Intracerebral hemorrhage and other serious neurologic events

Research in these fields often compares current standard care with newer strategies to improve safety, reduce complications, and support better everyday function.